FDA Approves Radioembolization Technology for Hepatocellular Carcinoma

Published by W Butcher on

The FDA approved TheraSphere Y-90 Glass Microspheres, a radioembolization technology, for the treatment of patients with hepatocellular carcinoma (HCC), according to a press release. The therapy was previously granted humanitarian device exemption, which limited the number of patients treated with the therapy per year. The technology is a type of selective internal radiation therapy comprised of microscopic glass beads containing radioactive yttrium. The beads are delivered directly to the tumors via a catheter, limiting patient toxicity.

Read More…

Categories: Uncategorized